Cargando…

Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models

AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wongjarupong, Nicha, Negron-Ocasio, Gabriela M, Chaiteerakij, Roongruedee, Addissie, Benyam D, Mohamed, Essa A, Mara, Kristin C, Harmsen, William S, Theobald, J Paul, Peters, Brian E, Balsanek, Joseph G, Ward, Melissa M, Giama, Nasra H, Venkatesh, Sudhakar K, Harnois, Denise M, Charlton, Michael R, Yamada, Hiroyuki, Algeciras-Schimnich, Alicia, Snyder, Melissa R, Therneau, Terry M, Roberts, Lewis R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871827/
https://www.ncbi.nlm.nih.gov/pubmed/29599607
http://dx.doi.org/10.3748/wjg.v24.i12.1321
_version_ 1783309705947381760
author Wongjarupong, Nicha
Negron-Ocasio, Gabriela M
Chaiteerakij, Roongruedee
Addissie, Benyam D
Mohamed, Essa A
Mara, Kristin C
Harmsen, William S
Theobald, J Paul
Peters, Brian E
Balsanek, Joseph G
Ward, Melissa M
Giama, Nasra H
Venkatesh, Sudhakar K
Harnois, Denise M
Charlton, Michael R
Yamada, Hiroyuki
Algeciras-Schimnich, Alicia
Snyder, Melissa R
Therneau, Terry M
Roberts, Lewis R
author_facet Wongjarupong, Nicha
Negron-Ocasio, Gabriela M
Chaiteerakij, Roongruedee
Addissie, Benyam D
Mohamed, Essa A
Mara, Kristin C
Harmsen, William S
Theobald, J Paul
Peters, Brian E
Balsanek, Joseph G
Ward, Melissa M
Giama, Nasra H
Venkatesh, Sudhakar K
Harnois, Denise M
Charlton, Michael R
Yamada, Hiroyuki
Algeciras-Schimnich, Alicia
Snyder, Melissa R
Therneau, Terry M
Roberts, Lewis R
author_sort Wongjarupong, Nicha
collection PubMed
description AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios (HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS: During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42 (1.18-5.00), 1.86 (0.98-3.52), and 2.83 (1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48 (1.15-1.91) and 1.59 (1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45 (1.06-1.98) and 1.38 (1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65, 0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant (S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION: BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter (S-LAD).
format Online
Article
Text
id pubmed-5871827
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-58718272018-03-29 Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models Wongjarupong, Nicha Negron-Ocasio, Gabriela M Chaiteerakij, Roongruedee Addissie, Benyam D Mohamed, Essa A Mara, Kristin C Harmsen, William S Theobald, J Paul Peters, Brian E Balsanek, Joseph G Ward, Melissa M Giama, Nasra H Venkatesh, Sudhakar K Harnois, Denise M Charlton, Michael R Yamada, Hiroyuki Algeciras-Schimnich, Alicia Snyder, Melissa R Therneau, Terry M Roberts, Lewis R World J Gastroenterol Retrospective Cohort Study AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios (HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS: During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42 (1.18-5.00), 1.86 (0.98-3.52), and 2.83 (1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48 (1.15-1.91) and 1.59 (1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45 (1.06-1.98) and 1.38 (1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65, 0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant (S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION: BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter (S-LAD). Baishideng Publishing Group Inc 2018-03-28 2018-03-28 /pmc/articles/PMC5871827/ /pubmed/29599607 http://dx.doi.org/10.3748/wjg.v24.i12.1321 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Wongjarupong, Nicha
Negron-Ocasio, Gabriela M
Chaiteerakij, Roongruedee
Addissie, Benyam D
Mohamed, Essa A
Mara, Kristin C
Harmsen, William S
Theobald, J Paul
Peters, Brian E
Balsanek, Joseph G
Ward, Melissa M
Giama, Nasra H
Venkatesh, Sudhakar K
Harnois, Denise M
Charlton, Michael R
Yamada, Hiroyuki
Algeciras-Schimnich, Alicia
Snyder, Melissa R
Therneau, Terry M
Roberts, Lewis R
Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title_full Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title_fullStr Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title_full_unstemmed Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title_short Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
title_sort model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the balad models
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871827/
https://www.ncbi.nlm.nih.gov/pubmed/29599607
http://dx.doi.org/10.3748/wjg.v24.i12.1321
work_keys_str_mv AT wongjarupongnicha modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT negronocasiogabrielam modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT chaiteerakijroongruedee modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT addissiebenyamd modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT mohamedessaa modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT marakristinc modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT harmsenwilliams modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT theobaldjpaul modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT petersbriane modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT balsanekjosephg modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT wardmelissam modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT giamanasrah modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT venkateshsudhakark modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT harnoisdenisem modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT charltonmichaelr modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT yamadahiroyuki modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT algecirasschimnichalicia modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT snydermelissar modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT therneauterrym modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels
AT robertslewisr modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels